Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Reviews of afamelanotide discuss nausea, headache, implant-site reactions, pigmentation changes, and broader safety considerations in the context of EPP treatment
However, for some, these symptoms can become severe enough to disrupt daily life or lead to medication discontinuation
This month's Broker Brief breaks down: - Why up to 65% of GLP-1 users discontinue within a year, and why that turns coverage into a sunk cost for employers - What oral GLP-1s like Lilly's Foundayo mean for demand, when most plans still have eligibility rules written for injectables only - How fast a PBM formulary decision can move, using this year's Zepbound to Wegovy switch and back as the case in point - Why 38% of employers already tie GLP-1 coverage to participation in a lifestyle or behavioral program If you're advising employers on GLP-1 coverage, this is where the conversation is heading
A: It can reflect increased training capacity, glycogen/water shifts, appetite changes, or lean mass gain rather than pure fat gain
